PRESS RELEASE ABBOTT PARK, Ill.,Sept. 2, 2015/PRNewswire/ –Abbott announced today that it provides completed its acquisition of Tendyne Holdings, Inc., a private medical device company focused on growing invasive mitral valve replacement therapies minimally. Abbott acquired the collateral of Tendyne that it didn’t already own for$225 millionupfront, producing a total transaction value of$250 million, plus potential future payments tied to regulatory milestones. ‘The Tendyne acquisition broadens Abbott's foundation as a leader in remedies for mitral valve disease, which is complicated and requires multiple treatment options highly,’ saidJohn M.The onset of an episode of typhoid or paratyphoid fever was considered to be the day of onset of fever that was reported during the first treatment visit for the episode. Study Oversight The institutional review boards at the International Vaccine Institute, the National Institute of Enteric and Cholera Diseases, and the Indian Council of Medical Analysis approved the protocol and monitored the progress of the scholarly study. All authors vouch for the completeness and accuracy of the data presented. There have been no agreements regarding confidentiality of the info among donors, the study sponsor , the vaccine producer, and the investigators. The vaccine manufacturer carried out serologic assays in a blinded way but played no role in the design of the study, in data analysis, or in the preparation of the manuscript.